This study is looking at how a special type of imaging, called 129Xe MRI/MRS, can help doctors understand the effects of a medication called sotatercept in people with pulmonary arterial hypertension (PAH). PAH is a condition where blood pressure in the arteries of the lungs is too high. Researchers want to see if 129Xe MRI/MRS can show changes in the lung's blood vessels that are caused by sotatercept. You might be able to join if you are an outpatient between 18 and 75 years old and have a confirmed diagnosis of PAH. The study aims to see if changes in the 129Xe MRI/MRS scans, specifically in red blood cell percentage and cardiogenic oscillation amplitudes, can predict how well sotatercept is working. The current status of this study is unclear, and it plans to enroll 14 participants.

Study design

This is an interventional study, meaning participants will receive a specific treatment (sotatercept) and undergo imaging. It plans to enroll 14 participants.

What's involved

You would have 129Xe MRI/MRS scans at the beginning of the study, and again at 3 and 12 months. You would also have standard medical assessments like lab tests and echocardiograms at each visit.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 12 months after starting the study, with assessments at 3 and 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.